March 22, 2017 — Samsung NeuroLogica announced that its portable computed tomography (CT) technology will be included in Carolinas HealthCare System’s Levine Cancer Institute’s innovative Mobile Lung CT Unit. The unit will bring lung cancer diagnosis and intervention to underserved populations in the Carolinas.
The mobile unit, constructed by Frazer Ltd. and funded by Bristol-Myers Squibb Foundation, is the only solution of its kind in the country, according to the company. Developed to address common barriers to screening including financial barriers, drive time and lack of public transportation, the Levine Cancer Institute mobile unit will enable patients to receive lung screenings and education about lung cancer in their own communities. Samsung NeuroLogica’s BodyTom is a central feature of the unit, featuring a portable, full-body, 32-slice CT scanner that delivers high-quality images of both soft tissue and bone. The system also features an 85cm gantry and 60cm field of view, the largest field of view available in a portable CT scanner, according to Samsung NeuroLogica.
Since the company introduced BodyTom in 2011, the scanner has been adopted and is now in use in over 100 centers worldwide. As a multi-departmental imaging solution, BodyTom is capable of transforming any room in the hospital — including long-term acute care (LTAC) settings, operating rooms, intensive care units, radiation oncology suites and emergency departments — into advanced imaging suites, eliminating the need to transport patients between departments.
BodyTom’s ability to provide versatile, real-time portable imaging enables healthcare providers to administer point-of-care CT to underserved populations with limited access to high quality healthcare. The mobile unit will decrease the time it takes to diagnose and initiate treatment for patients diagnosed with lung cancer, and reduce overall costs often associated with late-stage disease. In addition to lung cancer screenings, the mobile unit staff will offer smoking cessation education, and treatment navigation services to assist patients with any necessary follow-up intervention.
For more information: www.samsungneurologica.com
March 25, 2026 
